In BC, FAK activation has been shown to be required for ErbB2-mediated oncogenic transformation, invasion and tumor progression in vivo [64, 65], while SRC-mediated FAK tyrosine phosphorylation at multiple residues has been demonstrated to play an important role in full FAK activation [62, 63]. The gene discussed is ERBB2; the disease is breast cancer.